Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
Recruitment status was Recruiting
The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training. The hypothesis guiding this study is that Risperdal Consta, by improving verbal memory, will improve the ability to benefit from skills training interventions among schizophrenia patients. The primary objective of this study is to compare patients on Risperdal Consta to patients on other atypical antipsychotic medications in terms of their ability to benefit from skills training interventions. A secondary objective of this study is to determine whether patients taking Risperdal Consta improve in other areas of cognitive functioning and social functioning.
Drug: Risperdal Consta (drug)
Behavioral: Social Skills Training
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Efficacy of Risperidone Consta for Improving Ability to Benefit From Skills Training in Schizophrenia|
- Scores on an analogue measure of responsiveness to skills training.
- Scores on a measure of skills acquisition and performance pre-post a 3-month skills training group.
- Interview measures of social functioning.
- Neurocognitive functioning.
|Study Start Date:||September 2005|
|Estimated Study Completion Date:||August 2007|
|Contact: Steven M Silverstein, Ph.D.||(312) email@example.com|
|United States, Illinois|
|University of Illinois at Chicago||Recruiting|
|Chicago, Illinois, United States, 60612|
|Contact: Steven M Silverstein, Ph.D. 312-996-9515 firstname.lastname@example.org|
|Contact: Sarah Berten, B.A. (312) 355-4901 email@example.com|
|Principal Investigator: Steven M Silverstein, Ph.D.|
|United States, New York|
|New York Presbyterian Hospital||Not yet recruiting|
|White Plains, New York, United States, 10605|
|Contact: Adam Savitz, M.D., Ph.D. 914-997-4394 firstname.lastname@example.org|
|Principal Investigator: Adam Savitz, M.D., Ph.D.|
|Principal Investigator:||Steven M Silverstein, Ph.D.||University of Illinois at Chicago|